Format

Send to

Choose Destination
Blood Rev. 2015 Sep;29(5):329-34. doi: 10.1016/j.blre.2015.03.003. Epub 2015 Mar 27.

Cereblon binding molecules in multiple myeloma.

Author information

1
Mayo Clinic in AZ, Department of Hematology, USA.
2
Mayo Clinic in AZ, Department of Hematology, USA. Electronic address: Stewart.Keith@mayo.edu.

Abstract

Immunomodulation is an established treatment strategy in multiple myeloma with thalidomide and its derivatives lenalidomide and pomalidomide as its FDA approved representatives. Just recently the method of action of these cereblon binding molecules was deciphered and results from large phase 3 trials confirmed the backbone function of this drug family in various combination therapies. This review details the to-date knowledge concerning mechanism of IMiD action, clinical applications and plausible escape mechanisms in which cells may become resistant/refractory to cereblon binding molecule based treatment.

KEYWORDS:

Aiolos; Cereblon; Cereblon binding molecules; IMiDs; Ikaros; Lenalidomide; Multiple myeloma; Pomalidomide; Thalidomide

PMID:
25843596
DOI:
10.1016/j.blre.2015.03.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center